>
Switch to:

Allergy Therapeutics Debt-to-EBITDA

: -0.58 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allergy Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $2.5 Mil. Allergy Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $13.2 Mil. Allergy Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2021 was $-26.8 Mil. Allergy Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 was -0.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Allergy Therapeutics's Debt-to-EBITDA or its related term are showing as below:

OTCPK:AGYTF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67   Med: 0.37   Max: 17.42
Current: 1.35

-0.67
17.42

During the past 13 years, the highest Debt-to-EBITDA Ratio of Allergy Therapeutics was 17.42. The lowest was -0.67. And the median was 0.37.

OTCPK:AGYTF's Debt-to-EBITDA is ranked lower than
99.99% of the 49 Companies
in the Drug Manufacturers industry.

( Industry Median: 2.77 vs. OTCPK:AGYTF: 1.35 )

Allergy Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Allergy Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.42 -0.67 0.37 0.98 1.35

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 0.30 -1.09 0.34 -0.58

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Debt-to-EBITDA falls into.



Allergy Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allergy Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.4614305750351 + 13.207573632539) / 11.612903225806
=1.35

Allergy Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.4614305750351 + 13.207573632539) / -26.838709677419
=-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2021) EBITDA data.


Allergy Therapeutics  (OTCPK:AGYTF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Allergy Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)